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Abstract
B7-H4 is a newly identified B7 homolog that plays an important role in maintaining T-cell homeostasis by inhibiting T-cell
proliferation and lymphokine-secretion. In this study, we investigated the signal transduction pathways inhibited by B7-H4
engagement in mouse T cells. We found that treatment of CD3
+ T cells with a B7-H4.Ig fusion protein inhibits anti-CD3
elicited T-cell receptor (TCR)/CD28 signaling events, including phosphorylation of the MAP kinases, ERK, p38, and JNK. B7-
H4.Ig treatment also inhibited the phosphorylation of AKT kinase and impaired its kinase activity as assessed by the
phosphorylation of its endogenous substrate GSK-3. Expression of IL-2 is also reduced by B7-H4. In contrast, the
phosphorylation state of the TCR proximal tyrosine kinases ZAP70 and lymphocyte-specific protein tyrosine kinase (LCK) are
not affected by B7-H4 ligation. These results indicate that B7-H4 inhibits T-cell proliferation and IL-2 production through
interfering with activation of ERK, JNK, and AKT, but not of ZAP70 or LCK.
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Introduction
B7-H4 is an inhibitory member of the B7 family of co-
regulatory molecules which is expressed on antigen-presenting
cells as well as on non-immune cells and which interacts with an as
yet unidentified receptor(s) on activated T cells to inhibit T-cell
proliferation and IL-2 production [1–4]. The importance of B7-
H4 in regulating immune responses in vivo has been shown through
many studies. Administration of a B7-H4 mAb, that blocks B7-H4
action, to an experimental autoimmune encephalomyelitis (EAE)
mouse model promoted T-cell responses and exacerbated disease
[2]. Adenoviral-mediated transduction of islets with B7-H4, on the
other hand, protected them from rejection when transplanted into
allogeneic mice [5]. Studies into the mechanisms by which B7-H4
engagement prevents T-cell proliferation have shown that cells are
arrested at the G0/G1 phase of the cell cycle [1]. Addition of
exogenous IL-2 can partially reverse B7-H4–induced suppression
of T-cell proliferation, suggesting that inhibition of IL-2 produc-
tion is an important component of B7-H4 action on T cells.
Ligation of the T-cell receptor (TCR) in conjunction with co-
stimulatory receptors initiates a cascade of signal transduction
events that result in IL-2 production and T-cell clonal expansion
and differentiation [6]. The tyrosine kinase LCK is the first
signaling molecule to be activated downstream of the TCR [7].
Activated LCK phosphorylates ITAM motifs in the cytoplasmic
domain of the TCR gamma, epsilon and zeta chains [8]. ZAP70,
another tyrosine kinase, is recruited to the phosphorylated zeta
chain and is activated by phosphorylation of LCK. ZAP70 then
phosphorylates a number of downstream signaling molecules [9],
activating a signaling cascade which includes ERK and JNK
kinases, which leads to stimulation of IL-2 transcription [10].
However, these signaling pathways downstream of the TCR
network work in conjunction with signaling pathways downstream
of the co-stimulatory receptors. One of the key co-stimulatory
receptors is CD28, a positive signaling member of the B7 co-
regulatory family. CD28 interacts with its cognate ligands (CD80
and 86) on antigen-presenting cells, leading to activation of
phosphatidylinositide 3-kinase (PI3K). PI3K catalyzes the produc-
tion of phosphoinositol-3,4,5-triphosphate (PIP3) which functions
to activate PH domain–containing proteins such as the protein
kinase AKT. AKT is a master regulator involved in protein
synthesis, anti-apoptosis, cell survival/proliferation, and glucose
metabolism. Activation of PI3K/AKT pathway is a fundamental
requirement for cell-cycle progression and T-cell proliferation.
TCR activation in the absence of CD28 stimulation results in
impaired or altered T-cell responses ranging from decreased
proliferation/IL-2 production to anergy (non-responsiveness to
antigen) or apoptosis. The requirement for co-stimulatory receptor
signaling has been used to modulate T-cell responses for
therapeutic purpose. For example, much work has been focused
into clinical development the CTLA-4 molecule. CTLA-4 is
another member of the B7 family, but it functions to inhibit T-cell
activation. CTLA-4 is a surface protein that can be expressed on
activated T cells and competes with CD28 for binding to CD80/
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signalling. Soluble versions of CTLA-4 have been used clinically to
interfere with T-cell responses in autoimmunity and organ
transplantation. Studies of the signaling pathways which are
altered in T cells exposed to soluble CTLA-4 have confirmed
interference with PI3K-dependent events and also revealed an
inhibitory effect on ERK and JNK activation [11].
The signaling pathway(s) by which B7-H4 alters T-cell
responses, have not been well characterized. Based on our
knowledge of how the other inhibitory B7 family members
interfere with T-cell activation, we anticipate that B7-H4–
mediated signaling may inhibit MAPK and AKT kinases. In this
paper we examine this possibility and whether B7-H4 signaling
also alters LCK or ZAP70 activation. Characterization of the
molecular mechanism by which B7-H4 functions will provide
important information guiding rational use of B7-H4 therapy for
cancer, autoimmune diseases and transplantation.
Results
B7-H4 engagement inhibits T cell proliferation
We and others have shown previously that administration of a
soluble immunoglobulin fusion protein of B7-H4, B7-H4.Ig,
inhibited CD4
+ and CD8
+ T-cell proliferation upon TCR/
CD28 ligation [1–4]. However a question that has not been
addressed is whether the inhibitory effect of B7-H4.Ig adminis-
tration affects naı ¨ve and pre-activated T cells equally. We thus
compared the inhibitory effect of B7-H4.Ig on naı ¨ve splenic CD3
+
T cells versus the same cells which have been stimulated with CD3
for 16 h and rested for 30 h prior to use. Naı ¨ve or pre-activated
cells were cultured with a range of concentrations of anti-CD3
agonistic antibody, in the presence of a constant concentration of
an agonistic CD28 antibody, and with B7-H4.Ig or a control
human IgG1 Fc.Ig protein (Fc.Ig). As shown in Figure 1A and 1C,
although the calculated EC50 for CD3 was similar in both the
naı ¨ve and pre-activated cells (,0.15 mg/mL), maximum thymi-
dine incorporation was different. Thymidine incorporation
plateaued at 40610
3 cpm for pre-activated cells as compared to
27610
3 cpm for the naı ¨ve cells. Thus the pre-activated cells
proliferate much more vigorously than the naı ¨ve cells. However,
the ability of B7-H4.Ig to inhibit thymidine incorporation
appeared to be similar in both naı ¨ve and pre-activated cells. The
addition of B7-H4.Ig to the culture reduced thymidine incorpo-
ration by almost 50% in the presence of 0.3 mg/mL anti-CD3 in
both cell types.
We also tested the sensitivity of naı ¨ve vs. pre-activated cells to
B7-H4.Ig. In Figure 1B and 1D, the indicated concentration of
B7-H4.Ig was added to cultures in the presence of 0.3 mg/mL
anti-CD3 and 1 mg/mL anti-CD28. As seen in Figure 1B and 1D,
the naı ¨ve cells were more sensitive to B7-H4.Ig inhibition. At
10 mg/mL B7-H4.Ig, thymidine incorporation was inhibited by
60% in naı ¨ve cells (p=0.005). In contrast, the same concentration
of B7-H4.Ig inhibited thymidine incorporation in pre-activated
cells by only 40% (p=0.012). For the remainder of the studies in
this paper, we chose to use pre-activated cells because these cells
represent a more stringent system (i.e. cells are more resistant to
B7-H4.Ig) with which to examine the mechanism by which B7-
H4.Ig interferes with T-cell activation.
In order to determine the sensitivity of inhibition by B7-H4 on
different T-cell subsets, CD3
+, CD4
+, or CD8
+ T cells were
purified by magnetic beads. As shown in Figure 1E, B7-H4.Ig
protein inhibited thymidine incorporation in each subset to a
similar degree. The proliferation of total pre-activated CD3
+,
CD4
+, and CD8
+ was reduced by 50.3%, 57.9%, and 58.5%,
respectively. There were no significant differences in the ability of
B7-H4 to inhibit three T-cell subsets (p=0.6331).
We also examined the expression of the B7-H4 receptor on pre-
activated CD4
+ vs. CD8
+ T-cell subsets (Fig. 2). The B7-H4
receptor has not yet been identified, but it can be detected through
its binding of B7-H4.g [3]. Briefly, cells were incubated with
10 mg/mL of B7-H4.Ig or control Fc.Ig for 30 min, prior to
washing and detection of bound B7-H4.Ig using a PE conjugated
goat anti-human Ig Ab. B7-H4 receptor was detectable on pre-
activated CD3
+, CD4
+, or CD8
+ T cells starting at 3 days and
peaking at 4 to 5 days after stimulation (Fig. 2A). The mean
fluorescence intensity (MFI) of B7-H4.Ig staining was similar in all
three different subsets (Fig. 2B, p=0.55), indicating similar
expression of the B7-H4 receptor on pre-activated CD3
+, CD4
+,
or CD8
+ T cells. The inability to detect B7-H4.Ig binding prior to
3 days likely reflects the limitation of sensitivity of staining method
dependent on B7-H4.Ig protein binding followed by detection of
the bound B7-H4.Ig using an anti-Ig Ab. Our proliferation data
above indicates that cells are inhibited by B7-H4.Ig even at day 0
(naı ¨ve cells) after CD3/CD28 activation, at which time B7-H4.Ig
protein binding can’t be detected using current methods.
We also compared the responsiveness of CD3
+, CD4
+, or CD8
+
to B7-H4.Ig inhibition using readout that is more immediate than
proliferation assays. CD3
+, CD4
+, or CD8
+ were stimulated with
anti-CD3 for 16 h and rested for 30 h prior to use. Cells were then
stimulated with 5 mg/mL anti-CD3 and 2 mg/mL anti-CD28 in
the presence of 30 mg/mL Fc.Ig or B7-H4.Ig for the indicated
length of time. Cell lysates were prepared and subjected to
Western blot analysis to determine the levels of CD3/CD28
induced AKT phosphorylation on serine 473 using an AKT-
phospho-AKT-ser-473 Ab. AKT is a serine/threonine protein
kinase that is essential for multiple cellular processes including the
progression of cell cycle and T-cell proliferation and phosphor-
ylation on Ser-473 is a marker of its activation state (16). As shown
in Figure 3, anti-CD3/CD28 stimulation could induce AKT-Ser-
473 phosphorylation within 10 min. In the presence of B7-H4.Ig,
the level of p-AKT-Ser-473 was reduced by ,70% compared to
the Fc.Ig control in all three different T-cell subsets (Fig. 3B).
Our data show that CD3
+, CD4
+, or CD8
+ T cells all express
similar levels of the B7-H4.Ig receptor (Fig. 2) and respond to
similarly with respect to inhibition of AKT phosphorylation
(Fig. 3). We therefore used total CD3
+ T cells in the following
experiments.
B7-H4 engagement inhibits IL-2 production on T cells
We next determined the effect of B7-H4.Ig treatment on anti-
CD3/CD28–stimulated T-cell production of IL-2. Pre-activated T
cells were treated with 5 mg/mL anti-CD3 and 2 mg/mL anti-
CD28 in the presence of 30 mg/mL Fc.Ig or B7-H4.Ig for the
indicated length of time (Fig. 4A). RNAs were isolated and the
level of IL-2 mRNA was quantitated by quantitative PCR. In the
anti-CD3/CD28+Fc.Ig cells, IL-2 mRNA levels peaked at 4 h and
declined over the course of 24 h (Fig. 4A). The presence of B7-
H4.Ig dramatically reduced the amount of IL-2 mRNA detected
at 4 h, 16 h, and 24 h (p=0.001, 0.03, and 0.05). We also
collected the cell culture supernatant and measured IL-2 protein
levels by ELISA. As shown in Figure 4B, B7-H4.Ig also
significantly decreased IL-2 protein detected in the culture
supernatant at 16 h and 24 h (p=0.002 and 0.02, respectively).
In order to distinguish the relative contribution of different T cell
subsets on IL-2 secretion at single cell level, intracellular staining of
IL-2 was performed (Fig. 4C, 4D, 4E, and 4F). In concordance
with ELISA data (Fig. 4B), B7-H4 showed the most profound
inhibition on three T cell subsets at 16 h after stimulation
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+, CD4
+, and
CD8
+, respectively). At 4 h, a similar low level of IL-2 secretion
from T cells was observed using ELISA or FACS method (Fig. 4B,
4C, 4D, and 4E).
Activated T cells up-regulate the IL-2 receptor alpha chain
CD25 needed for high affinity binding of IL-2. Therefore, we
investigated whether the addition of B7-H4.Ig would interfere with
expression of CD25. Naı ¨ve cells were stimulated and rested as
described above. CD25 increased from 6% to 40% within 16 h,
but they decreased back to 15% during the 30-h rest period (data
not shown). Cells were then treated with anti-CD3/CD28 with
Fc.Ig or B7-H4.Ig as before, and the percent of cells expressing
CD25 were determined by flow cytometry. As shown in Figure 4G,
at 4 h after stimulation, the percent of cells which have
upregulated was 37% in Fc.Ig–treated cells vs. 26% in B7-
H4.Ig–treated cells (p=0.03). The relative lower level of inhibition
on CD25 (Fig. 4G, 29.7%) compared with on IL-2 (Fig. 4C, 4D,
4E, and 4F, 50–75%) suggested that inhibition on CD25 by B7-H4
might simply reflect the inhibition on T cell activation rather than
direct effect on IL-2 receptor. Alternatively, the ability of B7-H4
Figure 1. B7-H4 inhibits T-cell proliferation. Naı ¨ve (A and B) and pre-activated (C,D, and E) CD3
+ T cells were stimulated with various
concentrations of plate-bound anti-CD3 and soluble anti-CD28 (1 mg/mL) for 72 h. 18 h before harvest, cultures were pulsed with 1 mCi of [3H]-
thymidine. B7-H4.Ig or Fc.Ig was added at indicated concentrations (B and D). 10 mg/ml and 30 mg/ml of B7-H4.Ig or Fc.Ig was added for naı ¨ve and
pre-activated T cells, respectively. Pre-activated CD3
+, CD4
+, or CD8
+ T-cell subsets were stimulated with 0.3 mg/ml of plate-bound anti-CD3 and
soluble anti-CD28 (1 mg/ml). Triplicate wells were harvested and counted. Data represent three independent experiments and expressed as means 6
SEM. One star (*) indicates p,0.05, two stars (**) indicate p,0.01, and three stars (***) indicate p,0.001.’’
doi:10.1371/journal.pone.0028232.g001
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compared with its ability to inhibit IL-2.
B7-H4 engagement inhibits expression of the early
activation marker CD69
CD69 is another cell-surface molecule, the expression of which
is transiently induced on T cells early during the activation process
[12]. We also monitored CD69 expression in the cells used for the
CD25 expression studies above. In the pre-activation period, the
percent of cells expressing CD69 increased from 7% to 65% at
16 h (data not shown), decreasing almost to basal levels after a 30-
h rest (data not shown). Upon re-stimulation with anti-CD3/
CD28 (Fig. 4H), the percent of cells expressing CD69 increased to
71% in anti-CD3/CD28+Fc.Ig cells compared with 39% in anti-
CD3/CD28+B7-H4.Ig at 4 h (p=0.0004).
ERK activity is reduced upon B7-H4 engagement
One of the key pathways in transcription and expression of IL-2
involves the ERK1/2 kinases [13,14]. Therefore, we investigated
whether or not ERK1/2 activation would be affected by B7-H4
ligation. Cells were pre-activated and rested as before, and then
stimulated with anti-CD3/CD28 and Fc.Ig or B7-H4.Ig protein.
Cells lysates were prepared and subjected to immunoblot analysis
with antibodies to the phosphorylated, active form of ERK
[phospho-p44/42 MARK (ERK1/2) (Thr202/Tyr204)]. Phos-
phorylated ERK1/2 (p-ERK1/2) could be detected as early as
5 min, reaching maximal expression at 10 min, and decreasing to
minimal levels at 30 min (Fig. 5). After 60 min, the p-ERK
expression rebounded to a high level, likely due to the action of
autocrine IL-2. The expression of p-ERK1/2 was reduced with
B7-H4.Ig engagement at all time points (Fig. 5). For example, at
10 min, p-ERK1/2 reached peak levels. B7-H4.Ig treatment
reduced ERK1/2 phosphorylation to 7% of the level seen in the
Fc.Ig treated samples.
JNK activity is reduced upon B7-H4 engagement
JNK kinase is also involved in T-cell activation and IL-2
production [15,16]. We therefore also examined the effect of B7-
H4.Ig treatment on JNK phosphorylation as a measure of its
activation state. The samples from the ERK studies described
above were subjected to analyses with antibodies to phospho-
SAPK/JNK (Thr183/Tyr185). We found that phosphorylation of
Figure 2. Expression of B7-H4 receptor on activated T-cell
subsets. Naı ¨ve CD3
+, CD4
+, or CD8
+ T-cell subsets were stimulated
with 0.3 mg/ml of plate-bound anti-CD3 and soluble anti-CD28 (1 mg/
ml) for 16 h and then rested for 30 h prior to re-activation. Activated
CD3
+, CD4
+, or CD8
+ T-cell subsets were stimulated with plate-bound
anti-CD3 (5 mg/ml) and soluble anti-CD28 (2 mg/ml) for 4 d. Expression
of putative B7-H4 receptor was detected as follows. Cells were stained
with a control human IgG1 (filled) or with a B7-H4.hIgG1 (open),
followed by goat anti-human IgG-PE. (A). Representative histograms of
expression of B7-H4 receptor on CD3
+, CD4
+, or CD8
+ T-cell subsets. (B).
Mean fluorescence intensity (MFI) of B7-H4 receptor was plotted. There
is no significant difference in the expression of B7-H4 receptor among
three different T-cell subsets. Data represent 3 independent experi-
ments and are expressed as means 6 SEM.
doi:10.1371/journal.pone.0028232.g002
Figure 3. B7-H4 inhibits phosphorylation of AKT on different T
cell subsets similarly. Naı ¨ve CD3
+, CD4
+, or CD8
+ T-cell subsets were
stimulated with 0.3 mg/ml of plate-bound anti-CD3 and soluble anti-
CD28 (1 mg/ml) for 16 h and then rested for 30 h prior to re-activation.
Activated CD3
+, CD4
+, or CD8
+ T-cell subsets were stimulated with
plate-bound anti-CD3 (5 mg/ml) and soluble anti-CD28 (2 mg/ml) for
10 min. Representative western blot of protein extracts from CD3
+,
CD4
+, or CD8
+ T-cell subsets were detected by phosphorylated AKT
Ser473 (A) and quantitated by using Bio-Rad Quantity One program.
The y-axis was normalized for the loading control. B7-H4 treatment
significantly inhibited AKT phosphorylation at 10 min to a similar
degree on different T-cell subsets (B). Data represent 3 independent
experiments and are expressed as means 6 SD from 3–4 mice per
group.
doi:10.1371/journal.pone.0028232.g003
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anti-CD3/CD28 stimulation, reaching a maximum at 10 min,
and decreasing to a constant level thereafter (Fig. 5). B7-H4 clearly
reduced phosphorylation of JNK at all time points (Fig. 5), with
60% of JNK activity remaining at 10 min, demonstrating that B7-
H4 also interferes with JNK activity.
p38 activity is reduced upon B7-H4 engagement
The effect of B7-H4 on the third MAK kinase p38 was also
tested in the same lysates. We found that phosphorylation of p38
could be detected as early as 5 min in response to anti-CD3/
CD28 stimulation, reaching a maximum at 10 min, and
decreasing to a constant but slight lower level thereafter (Fig. 5).
B7-H4 clearly reduced phosphorylation of p38 at all time points
(Fig. 5), demonstrating that B7-H4 also interferes with p38 activity.
AKT activity is reduced upon B7-H4 engagement
As described above, CD28 co-receptor activation of the PI3K/
AKT pathway is essential for proliferation, IL-2 production and
prevention of development of anergy or tolerance. We probed the
lysates prepared above with antibodies to the phosphorylated
active form of AKT (phospho-AKT-Ser473). Phosphorylated
AKT (p-AKT-Ser473) could be seen as early as 1 min, increasing
to a plateau level at 60 min, which remained to 120 min in the
presence of anti-CD3/CD28 (Fig. 5). At time points up to and
including 60 min, B7-H4.Ig treatment significantly inhibited
phosphorylation of p-AKT-Ser473 to ,30% of the level in the
Fc.Ig samples (Fig. 5). Interestingly, inhibition at the 120-min time
point was only ,50%.
We next examined the effect of B7-H4.Ig treatment on the
phosphorylation state of GSK-3, an endogenous substrate of AKT
Figure 5. B7-H4 suppresses activation of ERK, JNK, p38, and AKT. Western blot analyses of protein extracts from CD3
+ T cells stimulated with
immobilized anti-CD3 (5 mg/mL) and soluble anti-CD28 (2 mg/mL). Fc.Ig or B7-H4.Ig was added after plate-bound anti-CD3 incubation. Representative
western blot for the detection of phosphorylated ERK1/2 Thr202/Tyr204, JNK Thr183/Tyr185, p38 Thr180/Tyr182, AKT Ser473, and GSK-3a/b Ser21/9
as indicated in the graph. p-ERK, JNK, p38, AKT, and GSK-3a/b activity were quantitated by using Bio-Rad Quantity One program. The y-axis was
normalized for the loading control. Data represent 3 independent experiments and are expressed as means 6 SD form 10–16 mice per group.
doi:10.1371/journal.pone.0028232.g005
Figure 4. B7-H4 inhibits IL-2, IL-2 receptor a chain (CD25), and CD69 expression. Pre-activated CD3
+ T cells were stimulated with anti-CD3
(5 mg/mL) and anti-CD28 (2 mg/mL) in the presence of B7-H4.Ig or Fc.Ig. Cells were collected for IL-2 mRNA detection (A) or IL-2 secretion (B), or
stained with anti-IL-2 (C, D, E, and F) or anti-CD25 (G) or CD69 (H) at the indicated time points. Relative expression of IL-2 mRNA was detected by real-
time PCR (A). Culture supernatant was collected and tested by ELISA (B). Representative dot plot of the expression of IL-2 secretion on CD3
+, CD4
+,
CD8
+ population and percentage of double positive IL-2 on three different subsets was shown (C). The average expression level of IL-2 on CD3
+,
CD4
+, and CD8
+ was shown in D, E, and F, respectively. Representative dot plot of CD25 expression and average expression level was shown (G). H.
Representative histogram of the expression of CD69 was plotted and the average expression level was quantitated using Bio-Rad Quantity One
program (H). 20,000 of Living cells were analyzed by flow cytometry. Data represent 3 independent experiments and are expressed as means 6 SD.
One star (*) indicates p,0.05, two stars (**) indicate p,0.01, and three stars (***) indicate p,0.001.
doi:10.1371/journal.pone.0028232.g004
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Immunoblots prepared as above were probed with antibodies to
phosphorylated GSK-3 (phospho-GSK-3a/b) (Ser21/9). The
kinetics of activation of GSK-3 phosphorylation in response to
anti-CD3/CD28 was similar to that of AKT-Ser473 phosphory-
lation, suggesting that p-AKT-Ser473 was a good surrogate
marker of kinase activity (Fig. 5). More importantly, B7-H4.Ig
treatment inhibited p-GSK-3 in the same way it did p-AKT-
Ser473, demonstrating that B7-H4.Ig also inhibited phosphoryla-
tion and activation of AKT enzymatic activity.
B7-H4 does not affect early parameters of TCR triggering
The signaling molecules we examined above are those which
CD28 co-receptor signaling regulates (either directly, AKT, GSK-
3 or indirectly, ERK, JNK). We next examined the effect of B7-
H4.Ig on two signaling molecules which the TCR directly
regulates with minimal input from co-receptor action. LCK and
ZAP70 tyrosine kinases are directly associated with the TCR
complex, and their activation state can be monitored by their
phosphorylation state. Phosphorylation of LCK and ZAP70 could
be seen as early as 1 min upon anti-CD3/CD28 stimulation, and
this was maintained up to 60 min (Fig. 6). B7-H4.Ig treatment did
not alter the phosphorylation of either LCK or ZAP-70.
Discussion
B7-H4 is a new member of the B7 family identified by searching
an expressed sequence tagged (EST) database for ESTs with
homology to the B7 family [1–3,18]. Investigation into the
biological role of B7-H4 revealed that B7-H4 ligation of its as-yet
unidentified receptor on T cells inhibits T-cell response and
function both in vitro and in vivo [1–5,19]. Based on these
observations, B7-H4.Ig protein is predicted to be able to modify
immune responses for therapeutic purpose. Indeed, the addition of
B7-H4.Ig protein inhibited the anti-CD3–induced proliferation of
activated T cells from patients with type 1 diabetes (T1D),
arresting CD4
+ T cell cycle progression in G0/G1 phase and
inducing apoptosis of both activated CD4
+ and CD8
+ T cells from
these patients. In addition, B7-H4.Ig inhibited the secretion of
IFN-c by PBMC from patients with T1D activated by b cell–
associated antigenic (insulin, GAD, and IA-2) peptides, and anti-
CD3 antibody. Ectopic expression of B7-H4 in human b cells also
protected these cells from cytotoxicity induced by b-cell antigen–
specific T-cell clones derived from T1D patients [4]. Local over-
expression of B7-H4 in islet allografts by a recombinant
adenovirus or insulinoma cell line NIT grafts by gene transduction
could similarly inhibit transplant rejection [5,19]. Tumors have
also taken advantage of the immunosuppressive properties of B7-
H4. A high level of B7-H4 protein was detected on various cancer
cells, including breast, lung, ovary, pancreas, and kidney,
suggesting that elevated levels of B7-H4 in the tumor environment
may be able to modulate T cells so as to escape immune
surveillance [20–24]. These studies provide compelling evidence
that over-expression of B7-H4 in tumors inhibits T-cell responses
through modulation of suppressive APC. The mechanism for this
inhibition on T cells by B7-H4 had been proposed to be in part
through Treg-stimulated B7-H4 expression on induction of APCs
[25]. However, the signaling pathways in T cells altered by B7-H4
ligation have not been well studied.
Production of IL-2 is a hallmark of T-cell activation. The
transcription and secretion of IL-2 by activated T cells promotes T
cell cycle progression, clonal expansion and effector function. We
found that IL-2 mRNA expression increased as early as 30 min in
pre-activated T cells upon TCR/CD28 stimulation. The IL-2R is
Figure 6. B7-H4 does not affect phosphorylation of LCK or ZAP70. Western blot analyses of protein extracts from CD3
+ T cells stimulated
with immobilized anti-CD3 (5 mg/mL) and soluble anti-CD28 (2 mg/mL) in the presence of control Ig or B7-H4.Ig. Representative western blot for the
detection of phosphorylated LCK and Zap70. p-LCK and ZAP70 were quantitated by using Bio-Rad Quantity One program. The y-axis was normalized
for the loading control. Data represent 3 independent experiments and are expressed as means 6 SD from 10–16 mice per group.
doi:10.1371/journal.pone.0028232.g006
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required for high affinity IL-2 binding, while the b and c chains
are responsible for the transduction of IL-2–generated signals. IL-
2R is upregulated by CD3/CD28 ligation through autocrine IL-
2–dependent and –independent mechanisms [26]. We found that
B7-H4.Ig inhibition of both IL-2 and CD25 expression occurred
with similar kinetics but to a different degree, suggesting that IL-2
and CD25 expression may be regulated through autocrine IL-2–
independent mechanisms. IL-2 gene transcription occurs in
activated T cells through the consequence of various signaling
pathways. Both the ERK and JNK kinase pathways have been
recognized as important regulators for IL-2 gene transcription. We
found in this study that both ERK and JNK activity was
stimulated upon anti-CD3/CD28 ligation and reduced in the
presence of B7-H4. CTLA-4, another potent negative regulator of
the B7 family, has also been reported to inhibit both TCR-induced
ERK and JNK activation [11]. It is interesting that B7-H4.Ig
inhibited ERK phosphorylation to a greater degree, with only 7%
of ERK activity remaining at 10 min (Fig. 5), than JNK
phosphorylation. This apparent preferential effect on ERK and
JNK and the question of whether B7-H4.Ig treatment leads to
inhibition of ERK and JNK kinases directly or via a molecule
upstream of these kinases is the subject of future investigation. The
inhibition of IL-2 mRNA levels by B7-H4.Ig appears to reduce at
24 h. This may be the result of the action of autocrine IL-2
accumulating in the culture, since the addition of exogenous IL-2
is known to be able to overcome the inhibitory effect of B7-H4
ligation [1–3].
CD28 co-receptor signaling is essential for productive T-cell
activation, especially of naı ¨ve or resting T cells. Blocking CD28
ligation impairs IL-2 production and can lead to T-cell anergy
and apoptosis [27,28]. Inhibition of CD28 co-receptor signaling
has been reported to alleviate T cell–dependent diseases [29,30].
Administration of anti-B7-H4 exacerbated mice EAE disease [2].
We have also shown that B7-H4.Ig addition induces apoptosis of
activated CD8
+ T cells from patients with T1D [4] and that in
vivo administration to allogeneic islet graft recipient mice is
associated with decreased CD8
+ T-cell levels in the graft and with
prolonged survival [5]. Consistent with the well described central
role of the PI3K/AKT pathway in CD28 signaling, we found
that B7-H4.Ig treatment significantly reduced AKT phosphory-
lation and kinase activity (as shown by the phosphorylation state
of GSK-3). Phosphorylation and activation of AKT is induced
directly by CD28 ligation [31–33] and also by the action of
cytokines such as IL-2 [34–36]. Our observation that B7-H4.Ig
treatment interferes with AKT activation has a number of
important corollaries. First, the observation that exogenously
added IL-2 can reverse the effect of B7-H4 action [1] may be due
to the fact IL-2 can activate PI3K/AKT via binding to the IL-2
receptor [35,36] and in this way compensate for the B7-H4.Ig
inhibition of CD28-induced AKT activation. Second, the greater
sensitivity of naı ¨ve vs. pre-activated cells to B7-H4.Ig protein may
be related to greater dependence of naı ¨ve cells on CD28 signaling
[27,28].
In contrast to the inhibitory effect of B7-H4.Ig treatment on
ERK, p38, JNK and AKT activation by anti-CD3/CD28, B7-
H4.Ig did not alter the phosphorylation state of LCK or ZAP70
tyrosine kinases. The activation and phosphorylation of these
kinases are regulated directly by ligation of TCR itself. LCK is
constitutively associated with the cytoplasmic domain of the co-
receptor molecules CD4 and CD8 [37] and is the first downstream
signaling molecule activated upon TCR ligation [7,38]. Upon
TCR stimulation, LCK (constitutively associated with the CD4/8
chains) autophosphorylates at tyrosine 394 in the activation loop
[39], resulting in its activation and the phosphorylation of
numerous substrates, include the intracellular domains of the
TCR chains. ZAP70 rapidly associates with the phosphorylated
CD3, which brings it in proximity to LCK. LCK phosphorylates
ZAP70 tyrosine 493 in its activation loop, also resulting in its
activation [40]. The phosphorylation state of these tyrosine
residues in their activation loops is a strong indicator of their
enzymatic activity. We did not observe any effect of B7-H4.Ig on
the phosphorylation state of these residues, and it remains to be
determined if B7-H4.Ig can alter the ability of these kinases to
access certain substrates. We note that the molecules for which we
did observe an effect of B7-H4.Ig are either entirely dependent on
CD28 signaling (AKT), or they integrate signals from CD28 (ERK
and JNK).
In summary, our data show for the first time that B7-H4.Ig
interferes with T-cell activation, at least in part through
antagonizing signaling pathways downstream of CD28. Future
studies will be directed towards characterizing the mechanism by
which B7-H4.Ig inhibits activation of AKT, ERK and JNK. From
the perspective of CD28 signaling, we will examine whether PI3K
activation is impaired and/or AKT phosphatases are activated.
From the perspective of B7-H4, its receptor on the T cell needs to
be identified and the nature of the signaling pathways downstream
of this receptor and/or its physical interaction with CD28 needs to
be determined. The current data have provided insight into how
B7-H4.Ig protein alters T-cell signaling and function that will be
useful to develop therapeutic strategies for B7-H4.Ig. For example,
monitoring CD25/69 expression could be a good biomarker for
B7-H4.Ig action and B7-H4.Ig might best be used in combination
with agents which target the TCR directly, or which target co-
receptor signaling in ways different than B7-H4.Ig.
Materials and Methods
T-cell stimulation
BALB/c mice were purchased from The Jackson Laboratory
and housed in the Jack Bell Research Centre under conventional
conditions. All mice were cared for according to the guidelines of
the Canadian Council and regulation of the University of British
Columbia. CD3
+, CD4
+, and CD8
+ T cells were purified from
mouse spleens by using magnetic negative selection (StemCell Inc.,
Vancouver, BC, Canada). The purity of T-cell subsets was more
than 95% by FACS analysis (FACSCanto, Becton Dickinson).
CD3
+, CD4
+, and CD8
+ T cells were cultured in tissue culture
plates that were pre-coated with anti-CD3e mAb (145-2C11, BD
Bioscience) at indicated concentrations with soluble anti-CD28
(clone 37.51, BD Bioscience). Pre-activated T cells were first
stimulated with anti-CD3e mAb at 0.3 mg/mL. These pre-
activated T cells were rested for 30 h before being re-activated
with the indicated amounts of plate-bound anti-CD3e mAb and
soluble anti-CD28.
Purification of B7-H4.Ig fusion protein
B7-H4.Ig was harvested from the supernatant of 293 cells with
transient transfection of B7-H4 cDNA in which the extracellular
domain was in-frame fused with human Ig G1 Fc fragment. This
B7-H4-containing supernatant was purified by Protein A affinity
chromatography (Bio-Rad, Mississauga, ON, Canada). The
purified B7-H4.Ig was quantitated by SDS-PAGE electrophoresis
with bovine serum albumin (BSA) as a standard control and
further confirmed by direct ELISA. Control human IgG1.Ig
protein was from Cedarlane Laboratories (Cedarlane, Burlington,
ON, Canada).
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3H]-thymidine incorporation assay
B7-H4.Ig or control human IgG1 Fc.Ig (Fc.Ig) was incubated in
96-well flat-bottom tissue culture plates that were pre-coated with
anti-CD3 antibody for 2 to 4 h at 37uC. Purified T cells (3610
4
cells per well) were cultured in RPMI-1640 medium supplemented
with 10% FCS, 2 mM glutamine, 100 u/mL penicillin, 100 mg/
mL streptomycin and 50 mM 2-mercaptoethanol for 72 h,
followed by pulse with addition of 1 mCi [
3H]-thymidine
(PerkinElmer, Montreal, QC, Canada) in the last 18 h. [
3H]-
thymidine incorporation was measured by liquid scintillation
counting.
Cytokine detection
IL-2 mRNA was quantitated by real-time PCR. RNA was
extracted with RNeasy mini kit (QIAGEN, Mississauga, ON,
Canada). cDNA was synthesized using reverse transcriptase
(GIBCO). Quantitative real-time PCR was done in duplicate
using 25 ng cDNA with 0.4 mM of each primer in a final reaction
volume of 20 mL containing 10 mLo f2 6SYBR PCR Master Mix
(QIAGEN). PCR parameters were as follows: 50uC for 2 min and
95uC for 10 min, followed by 45 cycles of 95uC for 15 sec, 55uC
for 20 sec and 72uC for 30 sec. Relative expression level was
calculated as 2
2(CTubiquitin2CTgene) (where CT is cycling threshold),
with ubiquitin RNA as the endogenous control for normalization.
The primer pairs for mouse IL-2 are as follows: forward, CCC
ACT TCA AGC TCC ACT TC, and reverse, ATC CTG GGG
AGT TTC AGG TT. Mouse GAPDH mRNA was used as an
internal control to confirm equivalent loading of the total RNA.
The production of IL-2 protein in the cell supernatants was
measured by sandwich ELISA with a pair of anti-IL-2 antibodies
(eBioscience, San Diego, CA, USA). Briefly, capture antibodies
(clone JES6-IA12) were coated at 2.5 mg/mL on NUNC ELISA
plates at 4uC overnight. After three washes, the coated plates were
blocked with PBS/3% BSA for 1 h at 37uC. The collected cell
supernatants and serial dilutions of recombinant mouse IL-2
standard protein (eBioscience) were added and incubated for 2 h
at 37uC. Biotinylated detection antibodies (clone JES6-5H4) were
added to capture the IL-2 protein, followed by Streptavidin-
HRPO incubation. TMB (Sigma, Oakville, ON, Canada) was
used as developing reagent. Absorbance was determined at
405 nm. Triplicate absorbance values of supernatant samples
were calculated according to standard recombinant IL-2 concen-
tration in ng/mL.
Western blot analyses
T cells were lysed in lysis buffer (150 mM sodium chloride,1.0%
NP-40, 50 mM Tris, pH 8.0) supplemented with a cocktail of
protease and phosphatase inhibitors (Roche, Laval, QC, Canada).
Lysates were made in 16SDS-PAGE buffer and boiled for 2 min
prior to separation by SDS-PAGE and electro-transferred to
nitrocellulose membranes (Bio-Rad). The amount of protein was
determined by Sigma protein assay to ensure equal protein loading
in each lane. Antibodies against phospho-ERK (Thr202/Tyr204),
phospho-p38 (Thr180/Tyr182), phospho-JNK (Thr183/Tyr185),
phospho-AKT (Ser473), phospho-GSK-3a/b (Ser21/9, GSK-3a
preferred), and phosphor-ZAP70 (Tyr319) were purchased from
Cell Signaling Technology (Danvers, MA, USA). Antibodies to
phospho-LCK (Tyr394) were from Santa Cruz Biotechnology.
Secondary antibody horseradish peroxidase conjugated goat
against rabbit was purchased from R&D (Minneapolis, MN,
USA). The blot was developed with Enhanced Chemilumines-
cence Plus Developer (Pierce, Nepean, ON, Canada) and
autographs were quantified using Bio-Rad Quantity One software
(Bio-Rad).
Flow cytometric analysis
2610
5 cells were re-suspended in 50 mL ice-cold PBS/1% calf
serum buffer and stained with anti-CD3, anti-CD69, anti-CD25,
or control rat IgG (eBioscience). Intracellular staining of IL-2 was
performed after 4 h stimulation with PMA plus Ionomycin
following the standard protocol (BD Biosciences, Mississauga,
ON, Canada). 20,000 live gated events were acquired on
FACScan, and Devo software was used to analyze relevant
populations.
For B7-H4 receptor detection, purified hIgG.Fc or mB7-
H4.hIgG.Fc (10 mg/mL) was ligated with T cells for 309 on ice,
followed by incubation with goat anti-human IgG PE for 209, the
expression of B7-H4 receptor was determined by its ability of
binding to B7-H4 fusion protein and expressed by mean
fluorescence intensity (MFI).
Statistical analysis
Two-tailed student’s t-test or ANOVA was used for comparison
between B7-H4.Ig and Fc.Ig treated groups. Data of the secretion
of IL-2 protein was analyzed by Prism 4.0 software (San Diego,
CA, USA). Differences were considered significant if p,0.05.
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